Abstract
Aura Biosciences (including serving on the board of directors 2013-2017), Infinity Pharmaceuticals (including serving on the board of directors 2013-2017), PMV Pharma Biotechnologies (including serving on the scientific advisory board 2014 to the present), Juno Therapeutics (acquired by Celgene) (including serving on the scientific advisory board 2014-2017), GRAIL, (including serving as member or chair of the scientific advisory board 2016-2018), Varian Medical Systems (including serving on the board of directors 2017-2018), Bristol-Myers Squibb (including serving on the board of directors March-September 2018), Seragon (acquired by Roche) (including serving on the scientific advisory board 2013-2014). J.B. also reports stock ownership in ApoGen Biotechnologies (including serving on the scientific advisory board 2014 to the present) and Foghorn Therapeutics (including serving on the board 2017 to the present); serving as cofounder of, receipt of fees from and stock ownership in Tango (formerly Synthetic Lethal) (2016 to the present) and Northern Biologics (formerly Mosaic Biomedicals) (including serving on the scientific advisory board 2013 to the present); receipt of consulting and travel fees from Novartis and Eli Lilly; and serving as cofounder of Venthera. J.R. reports non-financial support and reasonable reimbursement for travel from the European Journal of Cancer, Vall d'Hebron Institut of Oncology, the Chinese University of Hong Kong, SOLTI, Elsevier and GlaxoSmithKline, and receipt of consulting and travel fees from Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum Pharmaceuticals, Pfizer, Roche Pharmaceuticals and Ellipses Pharma (including serving on the scientific advisory board 2015 to the present).
